DiaMedica director granted 40,412 stock options

DiaMedica Therapeutics Inc. director Tanya Lewis received a grant of stock options as part of her compensation.

Rhea-AI Filing Summary

DiaMedica Therapeutics Inc. director Tanya Lewis received a grant of stock options as part of her compensation. She was awarded 40,412 stock options with a conversion or exercise price of $5.84 per share, giving her the right to buy Voting Common Shares at that price.

The options are scheduled to vest in four equal quarterly installments and will expire on June 1, 2036. Following this grant, she holds 40,412 derivative securities related to this award, indicating a routine, compensation-related acquisition rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 40,412 shares

Grant/Award 1 txn

Insider Lewis Tanya

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	40,412	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 40,412 contracts (Direct)

Footnotes (1)

1. F1. Scheduled to vest in four equal quarterly installments.

Key Figures

Stock options granted: 40,412 options Exercise price: $5.84 per share Post-grant option holdings: 40,412 derivative securities +2 more

5 metrics

Stock options granted 40,412 options Grant to director Tanya Lewis on June 1, 2026

Exercise price $5.84 per share Conversion or exercise price for Voting Common Shares

Post-grant option holdings 40,412 derivative securities Total stock options held after this award

Vesting schedule Four equal quarterly installments Footnote describing vesting of the option grant

Option expiration date June 1, 2036 Expiration of the granted stock options

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, conversion or exercise price, Voting Common Shares, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

conversion or exercise price financial

"conversion_or_exercise_price: 5.8400"

Voting Common Shares financial

"underlying_security_title: Voting Common Shares"

Scheduled to vest in four equal quarterly installments financial

"Footnote: Scheduled to vest in four equal quarterly installments."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tanya Lewis report in her DiaMedica (DMAC) Form 4 filing?

Tanya Lewis reported receiving a grant of 40,412 stock options for DiaMedica Therapeutics Inc. These options give her the right to buy Voting Common Shares at a set exercise price as part of her director compensation package.

What is the exercise price of Tanya Lewis’s DiaMedica (DMAC) stock options?

The granted stock options have an exercise price of $5.84 per share. This means Lewis can purchase DiaMedica Voting Common Shares at $5.84, regardless of the future market price, once the options vest and before they expire.

How many DiaMedica (DMAC) stock options does Tanya Lewis hold after this grant?

Following the transaction, Tanya Lewis holds 40,412 stock options tied to DiaMedica Voting Common Shares. This reflects the full amount of the new grant reported, a routine equity compensation award for her service as a director.

When do Tanya Lewis’s DiaMedica (DMAC) stock options vest?

The stock options are scheduled to vest in four equal quarterly installments. This means the award becomes exercisable in stages over one year, aligning the director’s compensation with ongoing service to DiaMedica Therapeutics Inc.

What is the expiration date of Tanya Lewis’s DiaMedica (DMAC) stock options?

The options granted to Tanya Lewis expire on June 1, 2036. She must exercise any vested options before that date to purchase DiaMedica Voting Common Shares at the stated $5.84 exercise price.

Is Tanya Lewis’s DiaMedica (DMAC) Form 4 a stock purchase or sale?

The Form 4 reports a grant of stock options, not an open-market stock purchase or sale. It is classified as a “Grant, award, or other acquisition” of derivative securities as part of her compensation, with no reported market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 05:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lewis Tanya

(Last) (First) (Middle)

301 CARLSON PARKWAY

SUITE 210

(Street)

MINNEAPOLIS MINNESOTA 55305

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DiaMedica Therapeutics Inc. [ DMAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.84	06/01/2026		A		40,412		(1)	06/01/2036	Voting Common Shares	40,412	$0	40,412	D

Explanation of Responses:

1. Scheduled to vest in four equal quarterly installments.

	/s/ Joshua L. Colburn, attorney-in-fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)